Paul S McNamara
Overview
Explore the profile of Paul S McNamara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maher R, Barry P, Emmott E, Jones A, Lin L, McNamara P, et al.
J Cyst Fibros
. 2023 Nov;
23(2):269-277.
PMID: 37951788
Background: There have been dramatic clinical improvements in people with cystic fibrosis (PwCF) commenced on the cystic fibrosis conductance regulator (CFTR) modulator elexacaftor/tezacaftor/ivacaftor (ETI). Sputum proteomics is a powerful research...
2.
Sposito F, Pennington S, David C, Duggan J, Northey S, Biagini G, et al.
Mucosal Immunol
. 2023 Aug;
16(6):776-787.
PMID: 37574128
Young age and high vitamin D plasma levels have been associated with lower SARS-CoV-2 infection risk and favourable disease outcomes. This study investigated mechanisms associated with differential responses to SARS-CoV-2...
3.
Sposito F, Northey S, Charras A, McNamara P, Hedrich C
Genes Immun
. 2023 Aug;
24(5):263-269.
PMID: 37573430
Nebulized hypertonic saline (3-7%) is commonly used to increase mucociliary clearance in patients with chronic airway disease and/or virus infections. However, altered salt concentrations may contribute to inflammatory responses. The...
4.
Maher R, Barrett E, Beynon R, Harman V, Jones A, McNamara P, et al.
Respir Med
. 2022 Oct;
204:107002.
PMID: 36274446
Background: Proteomics can reveal molecular pathways of disease and provide translational perspectives to inform clinical decision making. Although several studies have previously reported the cystic fibrosis airway proteome, the relationship...
5.
Maher R, Maatta M, Beynon R, Laurila H, McNamara P, Rajamaki M
BMC Vet Res
. 2022 Mar;
18(1):121.
PMID: 35354473
Background: Canine idiopathic pulmonary fibrosis (CIPF) is a chronic, progressive, interstitial fibrosing lung disease, manifesting as cough, exercise intolerance and ultimately, dyspnea and respiratory failure. It mainly affects West Highland...
6.
FitzMaurice T, McCann C, Nazareth D, McNamara P, Walshaw M
Radiology
. 2022 Mar;
303(3):675-681.
PMID: 35289662
Background Although spirometry is an important marker in the management of pulmonary exacerbations in cystic fibrosis (CF), it is a forced maneuver and can generate aerosol. Therefore, it may be...
7.
Rosala-Hallas A, Jones A, Williamson P, Bedson E, Compton V, Fernandes R, et al.
BMJ Open
. 2022 Mar;
12(3):e052943.
PMID: 35264343
Objectives: The objective of this study was to develop a core outcome set (COS) for use in future clinical trials in bronchiolitis. We wanted to find out which outcomes are...
8.
McNamara P, Clayton D, Burchett C, Compton V, Peak M, Clark J, et al.
PLoS One
. 2022 Feb;
17(2):e0263044.
PMID: 35113903
Background: Oxygen (O2) is a mainstay of treatment in acute severe asthma but how it is administered varies widely. The objectives were to examine whether a trial comparing humidified O2...
9.
FitzMaurice T, McCann C, Nazareth D, Shaw M, McNamara P, Walshaw M
J Cyst Fibros
. 2022 Feb;
21(6):1036-1041.
PMID: 35101365
Background: The CFTR modulator elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) leads to significant improvement in the symptoms and spirometry of people with cystic fibrosis (pwCF), but little evidence exists to understand its effect on...
10.
Shrwani K, Sharma R, Krishnan M, Jones T, Mayora-Neto M, Cantoni D, et al.
J Infect Dis
. 2021 Jun;
224(8):1305-1315.
PMID: 34161567
Background: A notable feature of coronavirus disease 2019 (COVID-19) is that children are less susceptible to severe disease. Children are known to experience more infections with endemic human coronaviruses (HCoVs)...